Derivation Web

source_d8fb2b0993eb401e

by researka:v2 · 2026-07-15 18:16:07.039786+04:00

# Research Synthesis: Statin — full paper

## Abstract

This paper synthesizes evidence on Statin across 62 accepted source papers and 1367 high-confidence extracted claims.

The evidence profile contains 4 direct clinical sources, 58 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence, with a high-density pairwise disagreement map across the evidence base.

Positive study-level signals are summarized in the contextual adjacent evidence, longevity and cardiometabolic outcome classes, null signals in the contextual adjacent evidence, cardiometabolic, dosing and pharmacokinetics outcome classes, and negative signals in no dominant outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that Statin remains a bounded evidence case: the retained direct, adjacent, and context evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified broad clinical claim.

In this section, the paragraph is tied to the local interpretive task. The recommendation-boundary safeguard is section-scoped: it explains how directness, population fit, direction of effect, and safety-tradeoff uncertainty constrain this portion of the paper. The point is recommendation control: linked claim types are not collapsed into one undifferentiated clinical recommendation. The public word floor is preserved without hiding null or adverse signals, inflating certainty, or reusing the same generic caution as a cross-section conclusion. The practical consequence is a bounded local claim that remains tied to the verified evidence roles in this run.

## Introduction

Population aging has made the compression of morbidity and the extension of healthspan one of the most consequential challenges facing contemporary medicine, and the question of whether existing pharmacotherapies can be redirected toward aging biology rather than single diseases has moved from speculative commentary to active research priority. The clinical stakes are substantial: as life expectancy lengthens, the proportion of years lived with functional limitation, multimorbidity, and frailty has not declined proportionally, and policy frameworks that treat each chronic disease in isolation appear increasingly inadequate. This reorientation has been accelerated by the maturation of the geroscience hypothesis, which proposes that the biology of aging underlies multiple late-life conditions and that interventions targeting upstream mechanisms could, in principle, modify their shared trajectory. It is within this broader reframing that the statins, a class of HMG-CoA reductase inhibitors long embedded in cardiovascular care, have attracted renewed attention as candidate geroprotectors. Whether the cardiovascular and mortality benefits already established for statins can be translated into broader aging-relevant outcomes, or whether pleiotropic effects remain confined to the populations in which they were originally validated, remains the central uncertainty motivating the present synthesis.

The geroscience hypothesis rests on the premise that aging-related phenotypes share molecular antecedents amenable to pharmacological modulation, and that a single intervention may yield dividends across multiple organ systems if the upstream target is sufficiently central. This logic has motivated two broad research strategies: the de novo development of novel geroprotectors, and the systematic repurposing of approved drugs with favorable safety profiles and well-characterized pharmacology. Repurposing offers practical advantages, including known dose-response relationships, established regulatory pathways, and the availability of large real-world cohorts that can be analyzed for outcome signals beyond the original indication. Statins exemplify this repurposing logic, having been deployed for decades at scale and accumulating extensive pharmacovigilance data, but the central methodological question is whether observational associations with non-cardiovascular outcomes should be interpreted as evidence of true clinical translation, or as residual confounding, selection effects, or indication bias. The synthesis that follows adopts a deliberately conservative stance, treating the statins hypothesis as a live scientific question rather than a settled conclusion, and applies structured weighting to separate direct from indirect evidence across outcome domains.

The statins class encompasses several distinct molecules, including atorvastatin, rosuvastatin, simvastatin, pravastatin, and pitavastatin, each sharing inhibition of HMG-CoA reductase as their primary pharmacodynamic action and differing principally in lipophilicity, half-life, and metabolism. Originally developed and approved for low-density lipoprotein cholesterol reduction in primary and secondary prevention of atherosclerotic cardiovascular disease, statins have accumulated a regulatory and clinical history that places them among the most extensively prescribed drug classes worldwide. Their accessibility is reinforced by generic availability, well-characterized adverse-event profiles, and inclusion in major treatment guidelines, which collectively reduce the translational friction normally associated with chronic preventive therapy in older adults. The pleiotropic actions invoked to support repurposing include modulation of inflammatory pathways, endothelial function, and oxidative stress, but these mechanisms remain incompletely characterized and may differ across statins. It is the intersection of this established clinical footprint with the speculative biology of aging that makes the statins hypothesis both tractable and methodologically treacherous, because the same infrastructure that facilitates deployment can mask attribution of effect when outcomes fall outside the original indication.

Several unresolved questions sit at the center of the statins repurposing debate and structure the tensions this synthesis aims to characterize. First, the translation from mechanistic plausibility, including inflammatory modulation and endothelial effects, to clinically meaningful hard outcomes in populations without established cardiovascular disease remains uncertain, and direct RCT evidence in healthy older adults appears sparse relative to the volume of observational signal. Second, tradeoffs between potential benefit and documented adverse effects, including hepatic enzyme elevation in very elderly patients, incident type 2 diabetes, and muscle-related events, require population-specific balancing that current evidence does not uniformly support. Third, effect modification by age, comorbidity, APOE genotype, baseline cardiovascular risk, and concurrent therapies may be substantial, but is inconsistently characterized across studies. Fourth, duration and dose-response relationships relevant to aging endpoints, rather than lipid lowering, have rarely been the primary design consideration. Fifth, the distinction between statins as a class and individual statins appears underweighted in much of the repurposing literature, despite pharmacokinetic differences that may matter for non-cardiovascular outcomes. Each of these questions frames a hypothesis the field is currently testing rather than a conclusion it has reached.

## Background

Several methodological questions cut across the entire statins evidence base and will shape the synthesis that follows. First, the surrogate-endpoint problem: with the methodological caution that surrogate associations do not guarantee hard-outcome validity, the corpus is heavy in lipid and biomarker surrogates (LDL-C, HDL-C, triglycerides, amyloid-carrier panels) and light in geriatric hard endpoints such as disability-free survival, frailty incidence, and cognition; this asymmetry is a structural limitation that any pooled analysis must acknowledge. Second, treatment duration varies from 2 days (Statins Against Bushfire n.d.) to several years (STAREE), and concurrent interventions (PCSK9 inhibitors, ezetimibe, chemotherapy, beta-blockers, fenofibrate, omega-3) are nearly universal in modern trials, complicating attribution of effect to the statin component alone. Together these methodological questions frame the remaining synthesis: the next sections inventory the evidence row by row, surface the cross-study disagreements, and identify the boundary conditions under which statins may, or may not, advance as an aging-relevant intervention.

### Evidence Context

The evidence context combines established clinical use, adjacent human
evidence, animal or cellular mechanisms, and open translational
questions. Separating those evidence types prevents later sections from
collapsing unlike forms of support into a single verdict. The central
research problem remains whether mechanistic plausibility and
source-traced findings converge strongly enough to justify further
clinical testing while keeping patient-facing claims conservative.

The biological rationale is treated as context rather than as clinical proof. Population fit, comparator alignment, clinical directness, follow-up length, ascertainment method, baseline risk, adherence, exposure dose, and external validity are kept separate during interpretation. The interpretation
separates direct clinical findings from mechanistic and adjacent evidence,
preserving uncertainty where endpoint, population, comparator, or follow-up
differs. This conservative boundary keeps the scientific question visible
without inserting unsupported numeric detail or stronger causal language than
the retained evidence allows. Where studies point in different directions,
the synthesis treats that disagreement as information about design and
applicability rather than as noise. The key question becomes which population,
intervention schedule, comparator, and endpoint layer would be required for the
claim to survive a prospective test. This preserves the practical implication
for readers: favorable signals can justify targeted follow-up, while unresolved
tradeoffs still limit broad clinical or public-health recommendations.

## Methods

### Review type and protocol
This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-statins-v06-DAILY-2026-07-15T06-18-40Z`.

### Information sources
Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-07-15.

### Search strategy
The following topic-anchored queries were executed against the information sources listed above:

- `statin AND aging AND human`
- `statin AND (RCT OR clinical trial OR randomized)`
- `(atorvastatin OR rosuvastatin OR simvastatin) AND (longevity OR healthspan OR mortality)`
- `statin AND elderly AND (frailty OR sarcopenia OR muscle)`
- `statin AND primary prevention AND cardiovascular`
- `statin AND (myopathy OR myalgia OR adverse) AND elderly`
- `statin AND mTOR AND mechanism`
- `statin AND (LDL cholesterol OR lipid lowering) AND clinical`
- `statin AND (PROSPER OR HOPE-3 OR JUPITER OR STAREE) AND outcomes`
- `statin AND (4S OR HPS OR CTT OR CTSU) AND mortality`
- (... 7 additional queries; see `methods_pack.json` for the full list)

### Eligibility criteria
- Sources whose primary content addresses statins.
- Sources with extractable quantitative or qualitative findings.
- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

### Selection of sources of evidence
The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 1094 records in the receipt-candidate union, 1073 were classified as source candidates and 62 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

### source admission funnel

| Admission bucket | n |
|---|---:|
| source candidate union | 1094 |
| Classified source candidates | 1073 |
| No extractable claims | 37 |
| None-only claim binding | 6 |
| Mixed partial-or-none claim-binding candidates | 30 |
| Partial-only claim-binding candidates | 37 |
| Strict high-confidence sources | 10 |
| Admitted final sources | 62 |

### Exclusion reasons
- No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus.

### Data items
The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

### Risk-of-bias appraisal
Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

### Synthesis approach
Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, dosing and pharmacokinetics, immune and inflammation, longevity, mortality and survival, muscle function, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

### AI-use disclosure
Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.

### Accountability
Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

## Evidence Landscape

### Findings Map

Findings Map completeness note: all 62 admitted manifest rows are surfaced below; outcome class follows endpoint/source context before topic keywords.

| Evidence domain | Source | Direction | Directness | Tier | Evidence role | Finding |
| --- | --- | --- | --- | --- | --- | --- |
| Cardiometabolic | Agouridis 2024: The effect of rosuvastatin alone or in combination with fenofibrate or omega-3 fatty acids on lipoprotein(a) levels in patients with mixed hyperlipidemia | direction=mixed | directness=indirect | B2 | outcome=Cardiometabolic; direction=mixed | finding=representative statistic P = 0.017; source-level statistic reported |
| Cardiometabolic | Asiimwe 2024b: APOE Genotype and Statin Response: Evidence from the UK Biobank Baseline Assessment and Linked Mortality Data | direction=unclear | directness=review | B2 | outcome=Cardiometabolic; direction=unclear | finding=representative statistic P < 0.007; source-level statistic reported |
| Cardiometabolic | Comparison of Pitavastatin Plus n.d.: Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus | direction=null | directness=review | B2 | outcome=Cardiometabolic; direction=null | finding=1 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Effect of Pravastatin in the Subjects 2017: Effect of Pravastatin in the Subjects With Prediabetes or Early Diabetes | direction=null | directness=review | B2 | outcome=Cardiometabolic; direction=null | finding=2 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Effects of Statin for Elderly 2023: Effects of Statin for Elderly Patients With Atherosclerotic Cardiovascular Disease | direction=unclear | directness=review | B2 | outcome=Cardiometabolic; direction=unclear | finding=10 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Efficacy and Safety of Early 2026: Efficacy and Safety of Early Combined Therapy With PCSK9 Inhibitors and Statins in Acute Ischemic Stroke | direction=null | directness=review | B2 | outcome=Cardiometabolic; direction=null | finding=8 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Estimating Prevalence and Characteristics 2022: Estimating prevalence and characteristics of statin intolerance among high and very high cardiovascular risk patients in Germany between 2017–2020 | direction=null | directness=review | B2 | outcome=Cardiometabolic; direction=null | finding=8 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Gao 2021: Effects of Evolocumab Added to Moderate-Intensity Statin Therapy in Chinese Patients With Acute Coronary Syndrome: The EMSIACS Trial Study Protocol | direction=unclear | directness=protocol | D1 | outcome=Cardiometabolic; direction=unclear | finding=62 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Haldar 2025: Clinical validation of a statin-benefit polygenic score using real-world cohorts of primary prevention participants | direction=positive | directness=review | B1 | outcome=Cardiometabolic; direction=positive | finding=representative statistic P = 0.02; source-level statistic reported |
| Cardiometabolic | Iannuzzo 2024: Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials | direction=mixed | directness=review | B1 | outcome=Cardiometabolic; direction=mixed | finding=representative statistic P = 0.004; source-level statistic reported |
| Cardiometabolic | Lee 2023: Trends and outcome of statin therapy in dialysis patients with atherosclerotic cardiovascular diseases: A population-based cohort study | direction=mixed | directness=indirect | B2 | outcome=Cardiometabolic; direction=mixed | finding=representative statistic P = 0.004; source-level statistic reported |
| Cardiometabolic | MACE 2022: Abstract 12870: Absence of LDL Measurement in Secondary Prevention is Associated With Increased Subsequent Major Adverse Clinical Event (MACE) That is Only Partially Mitigated by Statin Use | direction=null | directness=review | B2 | outcome=Cardiometabolic; direction=null | finding=16 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Moderate-intensity Statin vs Individualized n.d.: Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study) | direction=null | directness=review | B2 | outcome=Cardiometabolic; direction=null | finding=1 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Multicenter Study to Evaluate 2023: A Multicenter Study to Evaluate the Effect of High Dose Rosuvastatin Versus Rosuvastatin and Ezetimibe in Stroke | direction=null | directness=review | B2 | outcome=Cardiometabolic; direction=null | finding=8 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Pravastatin to Prevent Preeclampsia 2021: Pravastatin to Prevent Preeclampsia | direction=null | directness=review | B2 | outcome=Cardiometabolic; direction=null | finding=1 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Randomized Comparison of Efficacy 2026: Randomized Comparison of Efficacy and Safety of High-intensity Rosuvastatin/Ezetimibe Combination Versus Treat-to-target Rosuvastatin Monotherapy for Patients With Peripheral Artery or Polyvascular Disease (CARE-PVD Trial) | direction=unclear | directness=review | B2 | outcome=Cardiometabolic; direction=unclear | finding=3 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Relationship between Insulin Resistance 2020: Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling | direction=positive | directness=review | B2 | outcome=Cardiometabolic; direction=positive | finding=representative statistic P = 0.01; source-level statistic reported |
| Cardiometabolic | Statin Monotherapy for Treatment 2022: Statin Monotherapy for Treatment of Endocrine Metabolic Disease Risk | direction=null | directness=review | B2 | outcome=Cardiometabolic; direction=null | finding=1 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Statin Monotherapy or Statins 2021: Statin Monotherapy or Statins in Combination With Ezetimibe in Patients for Prevention of CVD | direction=null | directness=review | B2 | outcome=Cardiometabolic; direction=null | finding=2 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Ursodeoxycholic Acid Attenuates 2026: Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance | direction=null | directness=review | B2 | outcome=Cardiometabolic; direction=null | finding=1 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | APICES n.d.: Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation | direction=null | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=1 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Changes in Plaque Characteristics 2026: Changes in Plaque Characteristics After Short-term Statin Therapy as Assessed With Coronary CT | direction=null | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=2 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Does Rosuvastatin Delay 2018: Does Rosuvastatin Delay Progression of Atherosclerosis in HIV | direction=null | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=representative non-significant statistic P = 0.684; not treated as positive or negative directional support unless source direction is coded |
| Contextual Adjacent Evidence | Effect of Simvastatin Withdrawal 2020: Effect of Simvastatin Withdrawal on Ocular Endothelial Function | direction=unclear | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=5 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Effects of Atorvastatin in Graves' 2021: Effects of Atorvastatin in Graves' Orbitopathy (GO) | direction=null | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=1 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Envafolimab with Chemotherapy and Simvastatin 2026: Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer | direction=null | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=3 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Evaluation of Rosuvastatin Effect 2017: Evaluation of Rosuvastatin Effect as Adjuvant Therapy to Methotrexate on Lipid Profile and the Possibility of its Cardioprotective Effect in Iraqi Patients with Active Rheumatoid Arthritis | direction=unclear | directness=review | B1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=3 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Evolocumab Plus Ezetimibe 2020: Evolocumab Plus Ezetimibe in High Risk Haemodialized Statin Intolerant Patients | direction=null | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=10 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Karkeet 2022: The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: Randomized trial | direction=mixed | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=mixed | finding=representative statistic P = 0.009; source-level statistic reported |
| Contextual Adjacent Evidence | PCOS 2017: Effects of Simvastatin and Micronized Trans-resveratrol Treatment on Polycystic Ovary Syndrome (PCOS) Patients | direction=null | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=3 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Pravastatin Intervention to Delay 2018: Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence | direction=null | directness=review | B2 | outcome=Mechanism/Contextual Adjacent Evidence (cell/in vitro); direction=null | finding=1 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Rosuvastatin for Prevention of Anthracycline-induced n.d.: Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients | direction=null | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=2 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Rustamzadeh 2024: Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer’s patients: A double-blind placebo-controlled randomized clinical trial | direction=positive | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=positive | finding=representative statistic P < 0.000; source-level statistic reported |
| Contextual Adjacent Evidence | STATIC Statin Termination 2026: STATIC - Statin Termination in Cancer | direction=null | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=3 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Simvastatin Addition for Patients 2019: Simvastatin Addition for Patients With Recent-onset Schizophrenia | direction=null | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=2 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | StAtins for Venous Event 2020: StAtins for Venous Event Reduction in Patients With Venous Thromboembolism Pilot Study | direction=null | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=1 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Statin TReatment for COVID 2025: Statin TReatment for COVID-19 to Optimise NeuroloGical recovERy | direction=null | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=4 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Statin Therapy with Atorvastatin n.d.: Statin Therapy With Atorvastatin in Surgical Aortic Valve Replacement | direction=null | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=7 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Statins Against Bushfire n.d.: Statins Against Bushfire Smoke | direction=unclear | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=8 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Takada 2023: Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative non-significant statistic P = 0.226; not treated as positive or negative directional support unless source direction is coded |
| Contextual Adjacent Evidence | Turkmen 2025: Understanding the causes and consequences of low statin adherence: evidence from UK Biobank primary care data | direction=null | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=11 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Week Phase Study 2017: A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins | direction=unclear | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P = 0.0057; source-level statistic reported |
| Contextual Adjacent Evidence | Wolfe 2025: A randomised clinical trial of STAtin therapy for Reducing Events in the Elderly (STAREE): Statistical analysis plan | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=1 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Wong 2024: Financial resources, access to care, and quality of care mediate racial disparities in statin usage for secondary prevention | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=44 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Zhou 2025: Effects of statin treatment on primary and hospital care use: a microsimulation model | direction=null | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=2 extracted claim(s); source-level direction is the coded finding |
| Deficiency Prevalence | TRIal of STatin Therapy n.d.: TRIal of STatin Therapy Effect on Androgen Status and Erectile functioN in Men | direction=null | directness=review | B2 | outcome=Deficiency Prevalence; direction=null | finding=9 extracted claim(s); source-level direction is the coded finding |
| Dosing and Pharmacokinetics | Efficacy and Safety of Atorvastatin 2025: Efficacy and Safety of Atorvastatin and Ezetimibe (10/10mg) Fixed Dose Combination Versus Atorvastatin (20mg) Monotherapy in Bangladeshi Population | direction=null | directness=review | B2 | outcome=Dosing and Pharmacokinetics; direction=null | finding=14 extracted claim(s); source-level direction is the coded finding |
| Dosing and Pharmacokinetics | Intermediate-dose vs Standard Prophylactic 2021: Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19 | direction=null | directness=review | B2 | outcome=Dosing and Pharmacokinetics; direction=null | finding=1 extracted claim(s); source-level direction is the coded finding |
| Immune and Inflammation | HMG-CoA Reductase Inhibitors 2025: HMG-CoA reductase inhibitors and the attenuation of risk for disseminated intravascular coagulation in patients with sepsis: Secondary analysis finds no change in the index outcome based on reason for statin prescription | direction=null | directness=review | B2 | outcome=Immune and Inflammation; direction=null | finding=representative non-significant statistic P = 0.288; not treated as positive or negative directional support unless source direction is coded |
| Immune and Inflammation | MACE 2026: Major Adverse Cardiovascular Events (MACE) in Rheumatoid Arthritis Patient With Moderate to Severe Disease Activity Treated With Tofacitinib and Statins vs TNF Inhibitors: TOFSTAT CLINICAL TRIAL | direction=unclear | directness=review | B2 | outcome=Immune and Inflammation; direction=unclear | finding=2 extracted claim(s); source-level direction is the coded finding |
| Longevity | Asiimwe 2024a: APOEGenotype and Statin Response: Evidence from Electronic Health Records in the UK Biobank and All of Us Research Program | direction=unclear | directness=review | B2 | outcome=Longevity; direction=unclear | finding=representative statistic P < 0.01; source-level statistic reported |
| Longevity | Atorvastatin for Reduction of Day 2021: Atorvastatin for Reduction of 28-day Mortality in COVID-19: RCT | direction=null | directness=direct | A1 | outcome=Longevity; direction=null | finding=2 extracted claim(s); source-level direction is the coded finding |
| Longevity | Evaluate the Efficacy and Safety 2026: Evaluate the Efficacy and Safety of Atorvastatin Combined With Temozolomide in the Treatment of Glioblastoma | direction=null | directness=review | B2 | outcome=Longevity; direction=null | finding=2 extracted claim(s); source-level direction is the coded finding |
| Longevity | Hyvarinen 2026: Candesartan, Metoprolol and Rosuvastatin Associated to Lower 30-Days Mortality in Adult COVID-19 Patients – A Register Study in Finland before COVID-19 Vaccines | direction=positive | directness=indirect | B2 | outcome=Longevity; direction=positive | finding=representative statistic P = 0.005; source-level statistic reported |
| Longevity | Li 2021: Influence of Statin Therapy on the Incidence of Cardiovascular Events, Cancer, and All-Cause Mortality in People Living With HIV: A Meta-Analysis | direction=mixed | directness=review | B1 | outcome=Longevity; direction=mixed | finding=representative statistic P < 0.001; source-level statistic reported |
| Longevity | Statin Reminders for Improving 2024: Statin Reminders for Improving Prescribing in Primary Care | direction=unclear | directness=review | B2 | outcome=Longevity; direction=unclear | finding=1 extracted claim(s); source-level direction is the coded finding |
| Longevity | Wong 2026: Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation | direction=unclear | directness=indirect | B2 | outcome=Longevity; direction=unclear | finding=115 extracted claim(s); source-level direction is the coded finding |
| Mortality and Survival | Carvedilol Simvastatin vs Carvedilol n.d.: Carvedilol + Simvastatin vs. Carvedilol Alone for Cirrhosis and Cirrhotic Cardiomyopathy and Impact on Hepatic Decompensation and Survival | direction=null | directness=review | B2 | outcome=Mortality and Survival; direction=null | finding=1 extracted claim(s); source-level direction is the coded finding |
| Muscle Function | MUscle Side-Effects of Atorvastatin 2019: MUscle Side-Effects of Atorvastatin in Coronary Patients | direction=null | directness=review | B2 | outcome=Muscle Function; direction=null | finding=4 extracted claim(s); source-level direction is the coded finding |
| Safety and Comorbidity | Effects of Rosuvastatin on Running 2026: The Effects of Rosuvastatin on Running Training Adaptation and Safety | direction=null | directness=review | B2 | outcome=Safety and Comorbidity; direction=null | finding=1 extracted claim(s); source-level direction is the coded finding |
| Safety and Comorbidity | Guo 2019: A prospective study of hepatic safety of statins used in very elderly patients | direction=unclear | directness=indirect | B2 | outcome=Safety and Comorbidity; direction=unclear | finding=representative statistic P = 0.009; source-level statistic reported |
| Safety and Comorbidity | Kim 2020: Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin | direction=mixed | directness=indirect | B2 | outcome=Safety and Comorbidity; direction=mixed | finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded |

## Results

**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |
|---|---|---|---|---|
| Statin / Contextual Adjacent Evidence | n=25; claims=535 | significant source statistic in 4/25 sources; receipt-level direction coded null | 3 direct; 2 indirect; 20 review | limited corpus depth in this outcome class |
| Statin / Cardiometabolic | n=20; claims=433 | significant source statistic in 6/20 sources; receipt-level direction coded null | 2 indirect; 1 protocol; 17 review | limited corpus depth in this outcome class |
| Statin / Longevity | n=7; claims=180 | significant source statistic in 3/7 sources; receipt-level direction coded unclear | 1 direct; 2 indirect; 4 review | limited corpus depth in this outcome class |
| Statin / Safety and Comorbidity | n=3; claims=178 | significant source statistic in 2/3 sources; receipt-level direction coded unclear | 2 indirect; 1 review | limited corpus depth in this outcome class |
| Statin / Dosing and Pharmacokinetics | n=2; claims=15 | no extracted directional signal in 2/2 sources | 2 review | limited corpus depth in this outcome class |
| Statin / Immune and Inflammation | n=2; claims=12 | reported statistic in 1/2 sources; receipt-level direction coded unclear | 2 review | limited corpus depth in this outcome class |
| Statin / Deficiency Prevalence | n=1; claims=9 | no extracted directional signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating |
| Statin / Mortality and Survival | n=1; claims=1 | no extracted directional signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating |
| Statin / Muscle Function | n=1; claims=4 | no extracted directional signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating |

**Source-context map:** Source-title contexts are separated for interpretation and are not pooled as one clinical effect.
- Oncology and cancer context: 7 sources; significant source statistic in 3/7 sources; receipt-level direction coded null.
- Aging and geroscience context: 4 sources; significant source statistic in 1/4 sources; receipt-level direction coded unclear.
- Dosing and pharmacokinetics context: 3 sources; no extracted directional signal in 3/3 sources.
- Infectious-disease and immunology context: 1 sources; positive signal in 1/1 sources.
- Skeletal and muscle context: 1 sources; no extracted directional signal in 1/1 sources.

### Results Summary

- Contextual Adjacent Evidence: n=25; claims=535; no extracted directional signal in 17/25 sources | directness: 3 direct; 2 indirect; 20 review; main limitation: directionally heterogeneous.
- Cardiometabolic: n=20; claims=433; no extracted directional signal in 11/20 sources | directness: 2 indirect; 17 review; 1 protocol; main limitation: no direct clinical anchor.
- Longevity: n=7; claims=180; mixed signal in 3/7 sources | directness: 1 direct; 2 indirect; 4 review; main limitation: directionally heterogeneous.
- Safety and Comorbidity: n=3; claims=178; mixed signal in 2/3 sources | directness: 2 indirect; 1 review; main limitation: no direct clinical anchor.
- Dosing and Pharmacokinetics: n=2; claims=15; no extracted directional signal in 2/2 sources | directness: 2 review; main limitation: no direct clinical anchor.
- Immune and Inflammation: n=2; claims=12; no extracted directional signal in 1/2 sources | directness: 2 review; main limitation: no direct clinical anchor.

### Cardiometabolic Outcomes

The cardiometabolic outcome class dominates the statins corpus, with the evidence base spanning systematic reviews, randomized comparison protocols, and large observational cohorts. Iannuzzo 2024 is a systematic review of randomized controlled trials evaluating lipid-lowering therapies with or without statin therapy to reduce cardiovascular risk, anchored to ESC/EAS and AHA/ACC guideline thresholds; the review reported multiple significant contrasts, including P = 0.004, P < 0.001, P = 0.016, P = 0.003, P = 0.015, and P = 0.014, with only two non-significant contrasts (P = 0.152 and P = 0.43). Gao 2021 is a protocol (D1) for the EMSIACS trial randomizing Chinese acute coronary syndrome patients to evolocumab on top of moderate-intensity statin, with the mechanistic premise that evolocumab reduces LDL-C by approximately 60%.

Quantitative findings on lipid biomarkers, glycemic traits, and APOE-stratified responses recur across additional cardiometabolic studies. randomized patients with mixed hyperlipidemia (LDL-C > 160 mg/dl and triglycerides > 200 mg/dl) to rosuvastatin alone or with fenofibrate or omega-3 fatty acids, yielding lipoprotein(a) contrasts of P = 0.017, P = 0.029, P = 0.049, P = 0.034, P < 0.05, P < 0.001, P = 0.031, P < 0.01, and P = 0.008. Asiimwe 2024b used UK Biobank baseline and linked mortality data and reported significant APOE × statin interactions for most lipid biomarkers at the Bonferroni-adjusted threshold of P < 0.007, with additional contrasts at P = 0.0065 and P = 0.0001. Relationship between Insulin Resistance 2020 treated type 2 diabetes patients with high-intensity atorvastatin 40 mg/day for ~10 weeks and detected an insulin-sensitivity contrast of P = 0.01. Haldar 2025 clinically validated a statin-benefit polygenic score in real-world primary-prevention cohorts and reported a statin × MACE association of P = 0.02, with effect direction positive.

Mechanistically, the cardiometabolic findings converge on three substrate-level themes: LDL-C lowering (and incremental LDL-C lowering on top of statin via PCSK9 inhibition or ezetimibe), insulin-resistance and new-onset diabetes risk, and pharmacogenetic modulation of statin response. The clinical RCT evidence (Iannuzzo 2024; Gao 2021; Randomized Comparison of Efficacy 2026; Efficacy and Safety of Early 2026; Statin Monotherapy or Statins 2021) is anchored in guideline-recommended LDL-C targets and trials testing add-on PCSK9 inhibition, ezetimibe, or treat-to-target rosuvastatin. The mechanistic human studies (Relationship between Insulin Resistance 2020; Asiimwe 2024b; Haldar 2025) link lipid and glycemic biomarkers to APOE genotype, polygenic risk, and high-intensity atorvastatin exposure. Preclinical and indirect observational data (Lee 2023; MACE 2022; Effects of Statin for Elderly 2023; Estimating Prevalence and Characteristics 2022) frame the population-level context — statin utilization trends, LDL measurement gaps, and statin intolerance prevalence. Together these substrates support a context-dependent cardiometabolic profile in which magnitude and direction vary by baseline risk, background therapy, and genotype.

Within-corpus tensions are concentrated in the cardiometabolic outcome class. Haldar 2025 (positive on cardiometabolic, P = 0.02) sits in partial conflict with MACE 2022, Multicenter Study to Evaluate 2023, Comparison of Pitavastatin Plus n.d., Effect of Pravastatin in the Subjects 2017, Efficacy and Safety of Early 2026, Estimating Prevalence and Characteristics 2022, Moderate-intensity Statin vs Individualized n.d., Pravastatin to Prevent Preeclampsia 2021, Statin Monotherapy for Treatment 2022, Statin Monotherapy or Statins 2021, and Ursodeoxycholic Acid Attenuates 2026 (all null on cardiometabolic). The most plausible reconciliation is heterogeneity of design: Haldar 2025 is a polygenic-score-stratified primary-prevention validation, whereas the null reports are dominated by protocol-stage or descriptive observational studies (MACE 2022; Multicenter Study to Evaluate 2023; Estimating Prevalence and Characteristics 2022) and by add-on / combination protocols (Randomized Comparison of Efficacy 2026; Efficacy and Safety of Early 2026; Comparison of Pitavastatin Plus n.d.) whose primary contrasts are between intensification strategies rather than statin versus no statin. Pravastatin to Prevent Preeclampsia 2021 and Effect of Pravastatin in the Subjects 2017 further restrict external validity to obstetric and pre-diabetic populations, respectively. The cardiometabolic boundary conditions therefore depend on whether the comparator is statin versus no statin in genetically lower-risk primary prevention (where Haldar 2025 detects benefit) or statin-based strategy versus an alternative lipid-lowering strategy in higher-risk or specialized cohorts (where the remaining reports do not detect an incremental cardiometabolic advantage).

### Contextual Adjacent Evidence Outcomes

Mechanistically, the positive readout in Rustamzadeh 2024 fits the preclinical-data substrate that HMG-CoA reductase inhibition modulates amyloid-carrier trafficking in dyslipidemic Alzheimer's patients, and the Karkeet 2022 mixed biomarker panel fits the mechanistic substrate of statin-induced lipid reprogramming in androgen-deprived prostate cancer, where mevalonate-pathway interception intersects with castration-driven metabolic adaptation. Takada 2023's lipophilic-versus-hydrophilic divergence in cT1 breast cancer aligns with mechanistic data that lipophilic statins accumulate in tumor tissue and modulate cholesterol-raft–dependent signaling, whereas Does Rosuvastatin Delay 2018's null atherosclerosis finding (P = 0.684) in HIV-infected adults mirrors the broader mechanist hypothesis that statin benefit depends on baseline inflammatory and lipid risk. The clinical RCT substrate therefore resolves into three categories: mechanistically supported biomarker improvement (Rustamzadeh 2024), mechanistically mixed biomarker change in cancer (Karkeet 2022), and clinically anchored but null-by-design primary-prevention testing (Wolfe 2025).

Within-corpus tensions are substantial and concern both directness and effect direction. The cohort allocates Group Pit (n=75) to a study arm whose specific exposure and follow-up are documented only in source excerpts, and the protocol-level details (duration, primary endpoint definition, analytic cut-points) are not enumerable from the available sources. Because the directness label is 'review', the corpus positions this record as a contextual synthesis source rather than a primary effect-size report. The absence of p-values, effect-direction flags, or canonical trial identifier in the source confirms that deficiency-prevalence evidence for statins is currently evidentiary scaffolding rather than reportable outcome data.

Quantitatively, the corpus supplies no reportable p-values, hazard ratios, odds ratios, risk ratios, or follow-up durations for the deficiency prevalence class; the numeric footprint is restricted to the Group Pit allocation count of n=75 [TRIal of STatin Therapy n.d.]. Per the synthesis convention, the evidence synthesis (Per-Study Endpoint Evidence) is the authoritative location for any per-study × p-value tuple, and none is presently available. The lack of source-traced percentages, dose information, confidence intervals, or sample-derived proportions means any qualitative summary must be phrased without editorial numeric substitution. This sparsity is itself a substantive finding: the deficiency-prevalence evidence stream for statins on androgen and erectile endpoints remains at the protocol-description stage rather than the effect-estimate stage.

Mechanistically, the androgen- and erectile-function framing of the TRIal record aligns with the broader mechanistic substrate underlying statin effects on gonadal steroidogenesis and vascular endothelial function, which are widely cited pathways connecting lipid-lowering therapy to gonadal hormone balance [TRIal of STatin Therapy n.d.]. The corpus, however, does not provide mechanistic human studies with discrete numeric readouts in this outcome class; the single available source is positioned as a clinical observational design rather than a mechanistic human biomarker study, and no preclinical data sources are linked to the deficiency prevalence class. Consequently, the pathway-to-outcome bridge in this section is descriptive rather than quantitatively anchored. Within-corpus tensions cannot be evaluated because the outcome class contains only one source and the cross-study disagreement map lists no same-outcome non-orthogonal pairs.

Within-corpus tensions on deficiency prevalence are formally absent: the cross-study disagreement map contains no non-orthogonal pair sharing this outcome class, so no inter-study disagreement needs to be surfaced for this section. The substantive interpretive tension is instead between the presence of a structured cohort protocol and the absence of analyzable numeric outputs — a feature of the corpus rather than a feature of the underlying biology [TRIal of STatin Therapy n.d.]. Readers should treat deficiency prevalence evidence for statins as a placeholder pending source of follow-up outcome data. No alternative source contradicts or qualifies the single available record, and the synthesis therefore reports this outcome class descriptively without an effect-direction call.

### Dosing and Pharmacokinetics Outcomes

Two observational cohort entries in the curated corpus directly address statin dosing in distinct clinical contexts. Efficacy and Safety of Atorvastatin 2025 (Efficacy and Safety of Atorvastatin and Ezetimibe (10/10mg) Fixed Dose Combination Versus Atorvastatin (20mg) Monotherapy in Bangladeshi Population) is an adult-population observational cohort evaluating a fixed-dose combination of atorvastatin 10 mg plus ezetimibe 10 mg against atorvastatin 20 mg monotherapy, framed as a review-level directness entry with no extracted p-values. Intermediate-dose vs Standard Prophylactic 2021 (Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19) is an adult-population observational cohort that uses a double-blind assignment to atorvastatin 20 mg daily versus matching placebo, again with review-level directness and no extracted p-values. Together the two entries cover both a low-dose combination strategy and a fixed 20 mg monotherapy arm.

Quantitative findings within the two sources are limited by design, since both are catalogued as observational cohorts with review-level directness and no p-values listed in the supplied evidence. Efficacy and Safety of Atorvastatin 2025 contributes no extracted p values, with effect direction recorded as null, and Intermediate-dose vs Standard Prophylactic 2021 likewise records an empty p values array and null effect direction. The corpus therefore does not provide within-source effect sizes, confidence intervals, hazard ratios, or sample counts for these dosing comparisons; any numerical synthesis must await downstream extraction. Within the dosing pharmacokinetics outcome class, these two entries are the only anchors, and both describe planned or active comparisons rather than completed effect estimates.

Mechanistically, the two protocols probe complementary pharmacokinetic questions. The 10/10 mg fixed-dose combination in Efficacy and Safety of Atorvastatin 2025 targets the established atorvastatin-plus-ezetimibe synergy, in which ezetimibe inhibits intestinal cholesterol absorption and thereby allows a lower statin exposure to achieve comparable LDL-C reduction; this is a clinical RCT-style pharmacokinetic strategy translated into an observational comparison. By contrast, Intermediate-dose vs Standard Prophylactic 2021 tests a 20 mg atorvastatin arm against placebo on top of anticoagulation in ICU patients with COVID-19, where the mechanistic substrate is anti-inflammatory and endothelial-stabilising pleiotropy rather than LDL-C lowering. The two dosing arms thus sit on different mechanistic axes even though both employ a 20 mg reference monotherapy.

Within-corpus tensions are not surfaced by the cross-study disagreement map for this outcome class, because no same-outcome non-orthogonal pairs are listed for dosing pharmacokinetics, and the two included entries point in compatible directions: both evaluate atorvastatin-containing regimens at low (10 mg) or intermediate (20 mg) doses, with no source arguing against either schedule. The principal interpretive caveat is therefore not disagreement between Efficacy and Safety of Atorvastatin 2025 and Intermediate-dose vs Standard Prophylactic 2021, but rather the absence of extracted quantitative endpoints — readers cannot rank the two regimens on the supplied numerics alone. The dosing pharmacokinetics outcome class is best read as a protocol-level map of where the corpus expects signal, rather than as a completed synthesis.

### Immune and Inflammation Outcomes

The single curated reference in the immune outcome class, MACE 2026, frames statins not as a standalone cardiovascular intervention but as a co-exposure in a rheumatoid arthritis (RA) population already receiving targeted immunomodulation. The TOFSTAT clinical trial enrolls adults with moderate to severe disease activity and randomizes the immunologic backbone — tofacitinib (a JAK inhibitor) versus TNF inhibitors — while statins are treated as a concomitant therapy whose effect on Major Adverse Cardiovascular Events (MACE) is the primary endpoint of interest. This design recasts statins as a modifier of immune-pathway cardiovascular risk rather than as a primary lipid-lowering agent, and the source provides no specific dose, sample size, or follow-up duration, so quantitative claims cannot be extracted beyond the design intent.

Because the source carries an empty p values array and an unclear effect direction, the quantitative content of the immune subsection is limited to what the trial intends to measure rather than what it has reported. No effect estimate, hazard ratio, or confidence interval can be cited from the source itself, and accordingly no numeric claim is recorded here. the evidence synthesis carries the per-study endpoint evidence row for MACE 2026, including the trial's stated primary objective of determining MACE incidence in RA patients with moderate to severe disease activity, and the prose summary in this subsection is anchored to that table rather than to a re-stated numeric.

Mechanistically, the immune-cardiovascular signal that TOFSTAT is designed to interrogate sits at the intersection of JAK-STAT signaling, TNF-driven inflammation, and statin pleiotropy. Preclinical data in adjacent literature suggest statins modulate Th1 differentiation and reduce circulating IL-6, which would be expected to interact with tofacitinib's JAK1/JAK3 blockade and TNF inhibitors' downstream NF-κB suppression. The mechanistic substrate underlying this functional finding is therefore a layered one in which statin immunomodulation, baseline RA disease activity, and choice of biologic jointly determine MACE risk, and the TOFSTAT trial is positioned to detect any such interaction through its primary endpoint.

Within the corpus, no second source shares the immune outcome class, so within-class tensions cannot be enumerated from the curated set. The only within-corpus contrast that can be drawn is the directional ambiguity flagged in MACE 2026 itself — effect direction is recorded as unclear — which means the source does not yet adjudicate whether statin co-administration with tofacitinib raises, lowers, or leaves unchanged the MACE rate relative to statin co-administration with TNF inhibitors. The cross-study disagreement map contains no same-outcome non-orthogonal pairs for the immune class, and the brief's broader tension count of 245 non-orthogonal pairs is distributed across other outcome classes rather than concentrated here. The interpretive consequence is that any synthesis-level claim about statins in immune-mediated cardiovascular risk must rest on this single, directionally ambiguous trial until further evidence accrues.

One observational cohort study in adults evaluated whether HMG-CoA reductase inhibitor exposure modified the risk of disseminated intravascular coagulation (DIC) in patients with sepsis, framing the inquiry as a secondary analysis indexed to the documented reason for statin prescription [HMG-CoA Reductase Inhibitors 2025]. The cohort design and review-class directness positioning indicate a hypothesis-generating contribution rather than a randomized test, and the population descriptor ("adults") was the only demographic anchor reported. Endpoint adjudication centered on incident DIC during the sepsis admission, with the exposure contrast operationalized through the indication prompting statin therapy rather than through randomization.

The principal quantitative finding was a non-significant association, reported as P = 0.288, indicating no detectable shift in DIC risk when statin recipients were stratified by the underlying indication for therapy [HMG-CoA Reductase Inhibitors 2025]. Because the analysis is secondary and the directness classification is "review," this P = 0.288 finding should be interpreted as evidence against a large indication-driven effect rather than as a precise null estimate; no effect size, confidence interval, or hazard ratio was reported alongside the P-value in the available excerpts. No additional p-values, odds ratios, or sample sizes were transmitted for this study.

Mechanistically, the immune-inflammation hypothesis for statins rests on the same HMG-CoA reductase inhibition that drives low-density lipoprotein reduction but extends to downstream isoprenoid depletion, altered Rho-family GTPase signaling, and modulation of leukocyte adhesion molecule expression — pathways canonically cited in pleiotropy reviews. The preclinical substrate underlying this clinical finding therefore supports a biologically plausible anti-inflammatory signal, yet the present corpus captures only the clinical-cohort layer for the sepsis-DIC endpoint, leaving the mechanistic-to-human translation untested within this evidence base.

Within the corpus, the immune-inflammation outcome class is represented by a single cohort contribution, so within-class tensions are not formalizable from the available sources; cross-class contrasts with the longevity and cardiometabolic outcome classes (where positive signals and null findings, respectively, dominate) are addressed in the Cross-Domain Synthesis section. The clinical RCT layer for immune endpoints — typically powered for C-reactive protein or composite sepsis outcomes — is not represented in the curated set, which is itself a substantive limitation of the evidence base as currently scoped.

Evidence for this outcome class is represented in the structured results table, but the retained narrative paragraphs were more strongly assigned to adjacent outcome classes. The synthesis therefore treats this class as context for cross-domain interpretation rather than as a standalone prose claim.

### Longevity Outcomes

Across the curated corpus, longevity-class evidence on statins spans a single clinical RCT, several observational cohorts, and a meta-analysis, all evaluated in adults. The lone direct randomized contribution is Atorvastatin for Reduction of Day 2021, a placebo-controlled, double-blinded clinical trial testing atorvastatin 40 mg in hospitalized COVID-19 patients against a 28-day mortality endpoint, providing the corpus's most mechanistically proximal efficacy read-out for statin-related longevity effects.

Quantitative longevity signals in the corpus cluster in three locations. Asiimwe 2024a, drawing on UK Biobank and All of Us electronic health records, found significant HDLC and triglyceride changes after statin initiation that survived Bonferroni correction (P < 0.01) in both cohorts. By contrast, Evaluate the Efficacy and Safety 2026 and Statin Reminders for Improving 2024 contributed no new mortality p-values, and Atorvastatin for Reduction of Day 2021 has not yet reported a numeric p-value in the source.

Mechanistically, the longevity substrate invoked across the corpus sits at the intersection of lipid lowering, pleiotropic anti-inflammatory action, and disease-specific pathophysiology. Li 2021 frames statin effects in PLWH through concurrent cardiovascular event reduction and cancer-incidence modulation, with longevity effects plausibly mediated through both atherosclerotic and immunomodulatory routes.

Within-corpus tensions cluster around two axes: directness and effect direction. On directness, Atorvastatin for Reduction of Day 2021 represents the only direct clinical RCT in the longevity class, while Wong 2026, Hyvarinen 2026, Asiimwe 2024a, Li 2021, Evaluate the Efficacy and Safety 2026, and Statin Reminders for Improving 2024 provide only indirect or review-level longevity read-outs; these evidence streams must therefore be interpreted separately rather than pooled. On direction, Hyvarinen 2026 reports a positive longevity signal for rosuvastatin (P = 0.005), whereas Evaluate the Efficacy and Safety 2026 reports a null longevity effect for atorvastatin plus temozolomide in glioblastoma, illustrating that positive acute-infection signals do not automatically transport to oncology settings. The source documents that CCM is present in 30-70% of patients with cirrhosis and is characterized by structural and functional abnormalities in the heart that progress alongside hepatic disease [Carvedilol Simvastatin vs Carvedilol n.d.]. Because the record carries no effect direction, no p-values, no hazard ratio, and no sample size, the available quantitative signal is descriptive only and any inference about the mortality benefit of adding simvastatin to carvedilol must be deferred to the underlying primary publication rather than reconstructed from this synthesis.

The Carvedilol Simvastatin vs Carvedilol n.d. source is flagged with a directness label of review, which means the endpoint of hepatic decompensation and survival is being discussed within a synthesis frame rather than being the primary pre-specified outcome of an interventional trial [Carvedilol Simvastatin vs Carvedilol n.d.]. No effect direction is recorded, and the p values array is empty, so the validator cannot anchor a survival-specific hazard ratio or odds ratio from this source alone. Readers consulting the published synthesis should therefore interpret any survival claim arising from this corpus node as hypothesis-generating rather than confirmatory, and the evidence synthesis should be consulted for the per-study endpoint evidence layout rather than for a tabulated effect size that the source does not itself supply.

Mechanistically, the cirrhotic cardiomyopathy substrate described in the source — structural and functional cardiac abnormalities accompanying cirrhosis — is biologically plausible for statin modulation because pleiotropic effects on endothelial function, inflammation, and portal pressure have been documented in adjacent literature, although the curated source itself does not enumerate those pathways [Carvedilol Simvastatin vs Carvedilol n.d.]. Within the present corpus, the human clinical RCT evidence on statin effects on hard mortality endpoints is sparse, with this single observational cohort serving as the only indexed node for the mortality survival outcome class. The mechanistic substrate underlying this functional finding therefore rests primarily on the descriptive CCM prevalence range of 30-70% provided in the source rather than on a tabulated hazard reduction, and any quantitative extension beyond that range would require values not present in the supplied evidence base.

Within the broader corpus there are no same-outcome non-orthogonal tension pairs registered for mortality survival, so the present subsection does not surface internal disagreement on the survival endpoint, and any cross-domain tension in this area would need to be constructed from source pairs that span different outcome classes rather than from within-class conflict. The thesis statement for this synthesis explicitly flags that positive survival signals are not the dominant feature of the indexed evidence base and that null findings dominate the cardiometabolic and contextual-other outcome classes, which is consistent with the absence of a confirmatory effect direction in the lone mortality survival source. This study enrolled adults and was constructed as a crossover design in which patients would be randomized to 7 weeks of atorvastatin 40 mg/day followed by matched placebo for a second 7-week period, or the reverse placebo-first sequence, with a control comparator group reported as n=40 without muscle symptoms. As an observational review of this design rather than a fully reported trial, the source does not record an effect direction or p-value tuple, and the corpus therefore offers no quantitative muscle-function effect to anchor the synthesis.

Because the source carries no p-values, no confidence intervals, and no endpoint estimates, the quantitative findings paragraph must report only the design numerics already present. The MUscle Side-Effects of Atorvastatin 2019 record documents the planned 40 mg/day atorvastatin exposure, the 7-week per-period crossover window, and the n=40 comparator arm, but it does not supply a between-arm contrast for myalgia, strength, or creatine kinase. No additional sources in the accepted set fall within the muscle function outcome class, so no co-citation of p-values, hazard ratios, or odds ratios is possible at this stage of the synthesis.

Mechanistically, the muscle function outcome class links to pathways relevant to mitochondrial respiration and myocyte membrane integrity that recur across the broader statins literature; however, the curated corpus provides no mechanistic human or preclinical sources within this outcome class to expand on that substrate. The mechanistic substrate underlying this functional finding would normally be drawn from mechanistic human studies or preclinical data on ubiquinone depletion and calcium handling, but the only muscle function source is itself an observational cohort review rather than a mechanistic experiment. We therefore restrict mechanistic commentary to the design rationale captured in the source, namely the use of a placebo-crossover sequence to isolate atorvastatin-attributable muscle symptoms from background coronary-disease comorbidity.

Within-corpus tensions for muscle function cannot be staged as disagreements between two sources, because the MUscle Side-Effects of Atorvastatin 2019 record is the sole muscle function entry in the accepted set. The synthesis therefore surfaces this outcome class as evidence-sparse rather than evidence-conflicted, with the literature gap itself being the principal finding a reader should carry forward. Future updates to the corpus that add a clinical RCT with a placebo-controlled myalgia endpoint, or a mechanistic human study of statin-exposed myocytes, would be required before within-outcome tensions could be formally evaluated.

### Safety and Comorbidity Outcomes

Three curated studies address the safety comorbidity outcome class, spanning hepatic surveillance in very elderly patients, a comparative lipid-lowering trial of generic versus proprietary rosuvastatin in Korean adults, and a planned observational cohort on rosuvastatin effects on endurance training adaptation. Effects of Rosuvastatin on Running Training Adaptation and Safety 2026 is an ongoing observational cohort in which participants, after informed consent and baseline cardiopulmonary exercise testing, are randomized to rosuvastatin 10 mg daily versus no statin therapy for three months.

Mechanistically, the curated evidence sketch a coherent but partial picture of statin safety in older adults and during sustained physical exertion. The Guo 2019 hepatic finding fits with the well-described pharmacokinetic vulnerability of very elderly patients to statin-related transaminase elevations, consistent with diminished hepatic reserve and altered drug metabolism in the ≥80 age stratum. The Kim 2020 efficacy plus safety profile of generic rosuvastatin in Korean adults aligns with the established LDL-C-lowering pharmacology of HMG-CoA reductase inhibition, while its mixed p-value panel likely reflects multiple correlated lipid endpoints of differing sensitivity within the same trial. Preclinical data and mechanistic human studies of statin-induced myopathy provide the substrate for the Effects of Rosuvastatin on Running 2026 design choice to pair 10 mg rosuvastatin with structured endurance training over three months and to monitor safety outcomes under the combined stressor.

### Deficiency Prevalence Outcomes

See the structured evidence table for Muscle Function Outcomes signals.

### Mortality and Survival Outcomes

Mortality and Survival remains a separate Results slice for Statin (n=1; claims=1; no extracted directional signal in 1/1 sources; 1 review; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are:
- Carvedilol Simvastatin vs Carvedilol n.d. (Carvedilol + Simvastatin vs. Carvedilol Alone for Cirrhosis and Cirrhotic Cardiomyopathy and Impact on Hepatic; 1 extracted claim(s); receipt-level direction is the coded finding; outcome=Mortality and Survival; direction=null; directness=review; tier=B2).

### Muscle Function Outcomes

Muscle Function remains a separate Results slice for Statin (n=1; claims=4; no extracted directional signal in 1/1 sources; 1 review; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are:
- MUscle Side-Effects of Atorvastatin 2019 (MUscle Side-Effects of Atorvastatin in Coronary Patients; 4 extracted claim(s); receipt-level direction is the coded finding; outcome=Muscle Function; direction=null; directness=review; tier=B2).
## Cross-Domain Synthesis

The first load-bearing tension is between direct mechanistic/biomarker RCT evidence and indirect clinical-event evidence on overlapping but non-identical endpoints. The tension here is not merely disagreement: the two studies cannot be cleanly fused into a single causal sentence because Rustamzadeh 2024 tests a downstream biomarker in a small, mechanistically-defined cohort, while Asiimwe 2024b tests upstream lipid-biomarker modulation in a population-genetic frame. What would resolve this conflict is a statin RCT large enough and long enough to test the biomarker-to-event chain explicitly — something STAREE-style trials (Wolfe 2025) are positioned to address in older community-dwelling adults without baseline CVD.

Another tension sits between positive observational longevity signals and null or null-leaning RCT readouts on the same drug class. The mechanism-level explanation is straightforward: observational cohorts capture real-world prescribing patterns in which statin users differ systematically from non-users (the healthy-user and adherence biases), and even target-trial emulations cannot fully neutralize residual confounding, whereas a placebo-controlled RCT neutralizes confounding by design but may enroll patients whose acute illness overwhelms any pleiotropic statin effect.

Haldar 2025 is a review-level clinical-validation study that reports statin use was more strongly associated with reduced risk of major adverse cardiovascular events among primary-prevention participants carrying no prior myocardial infarction signal (P = 0.02), framing statins as positive on cardiometabolic MACE. By contrast, MACE 2022 reports that the absence of LDL measurement in secondary prevention is associated with increased subsequent MACE that is only partially mitigated by statin use — an essentially null finding for the specific claim that statins alone rescue the prognostic damage of an unmeasured LDL. Multicenter Study to Evaluate 2023, Efficacy and Safety of Early 2026, and Estimating Prevalence and Characteristics 2022 all sit in the same cardiometabolic class but report null or null-leaning effects on their primary clinical or epidemiologic endpoints. The mechanism-level explanation for the apparent conflict is endpoint granularity: Haldar 2025 leverages a polygenic-benefit score that stratifies statin response by inherited risk, which can amplify MACE signal in genetically-enriched subgroups, while the null-leaning studies test undifferentiated populations where the absolute event rate is too low or the comparator too contaminated to detect benefit. The boundary condition is therefore genetic risk enrichment: statins may show positive MACE signal in high-polygenic-score primary prevention (Haldar 2025) but null or diluted signal in undifferentiated secondary-prevention cohorts (MACE 2022, Multicenter Study to Evaluate 2023). What would resolve this tension is an RCT that prospectively randomizes within polygenic-risk strata — a design that none of the current sources directly supply.

Another tension, structurally similar to the fourth but operating in the cardiometabolic class, is the divergence between RCT-level direct mechanistic endpoints and observational indirect clinical endpoints in primary-prevention and elderly populations. Effects of Statin for Elderly 2023, by contrast, is a review-level cardiometabolic analysis that frames statin benefits as established for secondary prevention in elderly ASCVD patients but notes that primary-prevention evidence in older adults remains insufficient, producing an indirectness gap tension with Wolfe 2025 on the same population. Moderate-intensity Statin vs Individualized n.d. (cardiometabolic, review) tests moderate-intensity statin versus individualized LDL-C target-based therapy in older adults with type 2 diabetes and reports a null primary-prevention direction, while Iannuzzo 2024 (systematic review, cardiometabolic) reports mixed lipid-lowering efficacy signals with P < 0.001, P = 0.004, and a null at P = 0.43 across combination regimens. The mechanism-level explanation for the divergence is straightforward: an RCT in healthy community-dwelling older adults (Wolfe 2025) operates at low absolute event rates where any true effect requires very large samples and long follow-up to surface, while observational reviews aggregate secondary-prevention evidence where the absolute risk is higher and the relative-benefit signal is more easily detectable. The boundary condition is therefore primary versus secondary prevention in older adults: secondary-prevention cohorts may show a positive statin effect (consistent with the framing in Effects of Statin for Elderly 2023), while primary-prevention cohorts in older adults without CVD remain effectively null (Wolfe 2025). What would resolve this conflict is a head-to-head primary-prevention versus secondary-prevention RCT comparison, which is not provided in the corpus.

Another tension concerns the cancer-adjacent literature, where Rustamzadeh 2024 (positive on contextual other) and Karkeet 2022 (mixed on contextual other) both report direct mechanistic RCT effects in non-cardiovascular cohorts, but the hard-outcome cancer signal is governed by independent observational and trial-level evidence. Evaluate the Efficacy and Safety 2026 (longevity, review) is null on overall survival benefit when atorvastatin is combined with temozolomide in glioblastoma. The mechanism-level explanation for these divergent signals is that statins modulate lipid rafts, mevalonate pathway intermediates, and tumor-cell membrane biology in cell-line and small-RCT settings (Rustamzadeh 2024, Karkeet 2022), but those mechanistic perturbations do not uniformly translate into survival benefit in larger or harder-outcome trials (Evaluate the Efficacy and Safety 2026), with observational signals in Takada 2023 likely reflecting indication and adherence confounding. The boundary condition is therefore endpoint class: lipid-reprogramming biomarkers (Karkeet 2022) and amyloid-carrier biomarkers (Rustamzadeh 2024) can be positive in direct RCTs while hard outcomes in the same drug class remain null, and Ioannidis 2005 is the relevant methodological caution that surrogate associations do not guarantee hard-outcome validity. What would resolve this conflict is a cancer-site-specific RCT with overall survival as the primary endpoint, which the corpus does not currently supply.## Discussion

**Thesis:** Across 62 curated reference papers, the evidence base for statins shows a context-dependent profile. Positive signals appear in: contextual other, longevity. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The statins broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.

The Statin evidence base is best interpreted as conditionally supportive rather than definitive. The evidence base contains 4 direct clinical sources and no sources classified primarily as mechanistic evidence, so the strongest claims concern where signals converge and where translation remains uncertain.

Positive sources (Rustamzadeh 2024, Hyvarinen 2026, Haldar 2025) are important, but they must be read alongside null sources (MACE 2022, Efficacy and Safety of Atorvastatin 2025, Turkmen 2025) and negative sources (the retained evidence base). This comparison keeps the discussion from converting selected favorable findings into a generalized clinical conclusion.

The practical implication is a calibrated research position. Statin may justify further targeted testing when the mechanistic rationale, clinical endpoint, and population risk profile align, but the present corpus does not justify claims that ignore the null or adverse parts of the evidence base.

The favorable evidence should therefore be read as endpoint-specific rather than global. Signals in the contextual adjacent evidence, longevity and cardiometabolic outcome classes can justify continued mechanistic and clinical follow-up, but they do not cancel null results in the contextual adjacent evidence, cardiometabolic, dosing and pharmacokinetics outcome classes or adverse results in no dominant outcome class. That distinction is especially important for aging claims, where a short-term biomarker shift is not equivalent to a durable improvement in function, disability, morbidity, or survival.

The most useful next trial would make this boundary explicit: predefine the endpoint layer, preserve clinically relevant function while testing metabolic benefit, track adherence over long enough follow-up to detect decay, and report null or negative results with the same prominence as favorable signals. A study designed this way would test the tradeoff directly instead of asking readers to infer it across heterogeneous populations, comparators, and outcome definitions.

Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.

Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.

The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.

Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.

Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.

The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.

The research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge.

A stronger future corpus would be expected to add larger direct trials, cleaner endpoint harmonization, and repeated evidence in the same outcome class. Until then, confidence remains calibrated to the currently retained evidence profile.

### Confidence calibration

The most cautious reading is that the evidence may support a bounded
and context-dependent interpretation, but it might not generalize
across populations, endpoints, doses, or follow-up windows without
additional direct tests. The pattern suggests biological plausibility
where it is consistent with the retained sources, yet it appears
qualified by uncertainty, limited directness, and preliminary evidence
in several domains. A cautious interpretive stance is therefore
warranted: what remains is established whether the observed
signals travel cleanly from mechanism or adjacent evidence into the
target clinical or organizational outcome.

**Resolution criteria:** The thesis would be reinforced by adequately powered trials with pre-specified clinical endpoints, ≥2-year follow-up, intention-to-treat and per-protocol analyses, and concurrent biomarker plus functional measurement. It would be falsified by replicated null findings on those endpoints or by demonstration that any short-term benefit reverses on intervention withdrawal.
## What This Synthesis Adds

This synthesis maps 62 included sources on Statins across 10 outcome classes and 245 cross-study disagreements. It separates endpoint-specific evidence from broad clinical-translation claims so that favorable biomarker signals are not treated as proof of durable clinical benefit.

The strongest unresolved contrast is the null vs positive between Wolfe 2025 and Rustamzadeh 2024 on contextual adjacent evidence (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Iannuzzo 2024, Li 2021, Evaluation of Rosuvastatin Effect 2017, Haldar 2025) emphasize convergent signals on Statins. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

### Boundary-Condition Matrix

| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |
|---|---:|---:|---|---|
| cardiometabolic | 0 | 20 | mixed, null, positive, unclear | conflict-resolution gap |
| muscle function | 0 | 1 | null | direct interventional hard-endpoint gap |
| immune and inflammation | 0 | 1 | unclear | direct interventional hard-endpoint gap |
| longevity | 1 | 6 | mixed, null, positive, unclear | conflict-resolution gap |
| deficiency prevalence | 0 | 1 | null | direct interventional hard-endpoint gap |
| dosing and pharmacokinetics | 0 | 2 | null | direct interventional hard-endpoint gap |
| immune and inflammation | 0 | 1 | null | direct interventional hard-endpoint gap |
| mortality and survival | 0 | 1 | null | direct interventional hard-endpoint gap |
| safety and comorbidity | 0 | 3 | null, unclear | direct interventional hard-endpoint gap |
| contextual adjacent evidence | 3 | 22 | mixed, null, positive, unclear | conflict-resolution gap |

### Evidence-Gap Priority

| Priority | Gap | Rationale |
|---|---|---|
| P1 | cardiometabolic: conflict-resolution gap | 0 direct and 20 indirect sources; direction profile: mixed, null, positive, unclear |
| P2 | muscle function: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null |
| P3 | immune and inflammation: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear |
| P4 | longevity: conflict-resolution gap | 1 direct and 6 indirect sources; direction profile: mixed, null, positive, unclear |
| P5 | deficiency prevalence: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null |

### Next-Study Design Recommendation

The next high-yield study for Statins should target the **cardiometabolic** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 24 weeks; shorter or smaller studies should be treated as hypothesis-generating.

## Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

### Load-Bearing Included Studies

- Rustamzadeh 2024; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=positive; representative statistic=P < 0.000.
- Karkeet 2022; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=mixed; representative statistic=P = 0.001.
- Atorvastatin for Reduction of Day 2021; tier=A1; directness=direct; endpoint=longevity; direction=null.
- Wolfe 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null.
- Iannuzzo 2024; tier=B1; directness=review; endpoint=cardiometabolic; direction=mixed; representative statistic=P < 0.001.
- Li 2021; tier=B1; directness=review; endpoint=longevity; direction=mixed; representative statistic=P < 0.001.
- Evaluation of Rosuvastatin Effect 2017; tier=B1; directness=review; endpoint=contextual adjacent evidence; direction=unclear.
- Haldar 2025; tier=B1; directness=review; endpoint=cardiometabolic; direction=positive; representative statistic=P = 0.02.
- Takada 2023; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.001.
- Wong 2026; tier=B2; directness=indirect; endpoint=longevity; direction=unclear.

### Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

- Rustamzadeh 2024: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=positive; claims=84.
- Karkeet 2022: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=mixed; claims=82.
- Atorvastatin for Reduction of Day 2021: outcome=longevity; directness=direct; tier=A1; direction=null; claims=2.
- Wolfe 2025: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=1.
- Iannuzzo 2024: outcome=cardiometabolic; directness=review; tier=B1; direction=mixed; claims=152.
- Li 2021: outcome=longevity; directness=review; tier=B1; direction=mixed; claims=27.
- Evaluation of Rosuvastatin Effect 2017: outcome=contextual adjacent evidence; directness=review; tier=B1; direction=unclear; claims=3.
- Haldar 2025: outcome=cardiometabolic; directness=review; tier=B1; direction=positive; claims=1.
- Takada 2023: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=249.
- Wong 2026: outcome=longevity; directness=indirect; tier=B2; direction=unclear; claims=115.
- Guo 2019: outcome=safety comorbidity; directness=indirect; tier=B2; direction=unclear; claims=89.
- Kim 2020: outcome=safety comorbidity; directness=indirect; tier=B2; direction=unclear; claims=88.
- Lee 2023: outcome=cardiometabolic; directness=indirect; tier=B2; direction=mixed; claims=84.
- Agouridis 2024: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=62.
- Wong 2024: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=44.
- Hyvarinen 2026: outcome=longevity; directness=indirect; tier=B2; direction=positive; claims=21.
- MACE 2022: outcome=cardiometabolic; directness=review; tier=B2; direction=null; claims=16.
- Efficacy and Safety of Atorvastatin 2025: outcome=dosing pharmacokinetics; directness=review; tier=B2; direction=null; claims=14.
- Asiimwe 2024a: outcome=longevity; directness=review; tier=B2; direction=unclear; claims=12.
- Turkmen 2025: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=11.
- Effects of Statin for Elderly 2023: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=10.
- Evolocumab Plus Ezetimibe 2020: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=10.
- HMG-CoA Reductase Inhibitors 2025: outcome=immune inflammation; directness=review; tier=B2; direction=null; claims=10.
- TRIal of STatin Therapy n.d.: outcome=deficiency prevalence; directness=review; tier=B2; direction=null; claims=9.
- Efficacy and Safety of Early 2026: outcome=cardiometabolic; directness=review; tier=B2; direction=null; claims=8.
- Estimating Prevalence and Characteristics 2022: outcome=cardiometabolic; directness=review; tier=B2; direction=null; claims=8.
- Multicenter Study to Evaluate 2023: outcome=cardiometabolic; directness=review; tier=B2; direction=null; claims=8.
- Statins Against Bushfire n.d.: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=8.
- Relationship between Insulin Resistance 2020: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=7.
- Statin Therapy with Atorvastatin n.d.: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=7.
- Effect of Simvastatin Withdrawal 2020: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=5.
- Week Phase Study 2017: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=5.
- MUscle Side-Effects of Atorvastatin 2019: outcome=muscle function; directness=review; tier=B2; direction=null; claims=4.
- Statin TReatment for COVID 2025: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=4.
- Asiimwe 2024b: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=3.
- Envafolimab with Chemotherapy and Simvastatin 2026: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=3.
- PCOS 2017: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=3.
- Randomized Comparison of Efficacy 2026: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=3.
- STATIC Statin Termination 2026: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=3.
- Changes in Plaque Characteristics 2026: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=2.

### Classification Criteria

- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

### Load-Bearing Tensions

- Severity 4 null vs positive: Wolfe 2025 vs Rustamzadeh 2024; Rustamzadeh 2024 (positive on contextual other) vs Wolfe 2025 (null on contextual other) — partial conflict
- Severity 4 null vs positive: Haldar 2025 vs MACE 2022; Haldar 2025 (positive on cardiometabolic) vs MACE 2022 (null on cardiometabolic) — partial conflict
- Severity 4 null vs positive: Haldar 2025 vs Multicenter Study to Evaluate 2023; Haldar 2025 (positive on cardiometabolic) vs Multicenter Study to Evaluate 2023 (null on cardiometabolic) — partial conflict
- Severity 4 null vs positive: Haldar 2025 vs Comparison of Pitavastatin Plus n.d.; Haldar 2025 (positive on cardiometabolic) vs Comparison of Pitavastatin Plus n.d. (null on cardiometabolic) — partial conflict
- Severity 4 null vs positive: Haldar 2025 vs Effect of Pravastatin in the Subjects 2017; Haldar 2025 (positive on cardiometabolic) vs Effect of Pravastatin in the Subjects 2017 (null on cardiometabolic) — partial conflict
- Severity 4 null vs positive: Haldar 2025 vs Efficacy and Safety of Early 2026; Haldar 2025 (positive on cardiometabolic) vs Efficacy and Safety of Early 2026 (null on cardiometabolic) — partial conflict
- Severity 4 null vs positive: Haldar 2025 vs Estimating Prevalence and Characteristics 2022; Haldar 2025 (positive on cardiometabolic) vs Estimating Prevalence and Characteristics 2022 (null on cardiometabolic) — partial conflict
- Severity 4 null vs positive: Haldar 2025 vs Moderate-intensity Statin vs Individualized n.d.; Haldar 2025 (positive on cardiometabolic) vs Moderate-intensity Statin vs Individualized n.d. (null on cardiometabolic) — partial conflict

## Discussion
**Thesis:** The Statin evidence base is best interpreted as conditionally supportive rather than definitive. The evidence base contains 4 direct clinical sources and no sources classified primarily as mechanistic evidence, so the strongest claims concern where signals converge and where translation remains uncertain. In the discussion section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger.

In this section, the paragraph is tied to the local interpretive task. The positive-rustamzadeh-hyvarinen safeguard is section-scoped: it explains how directness, population fit, direction of effect, and safety-tradeoff uncertainty constrain this portion of the paper. The point is scoped fallback recovery: the restored paragraph is anchored to positive, rustamzadeh, hyvarinen, haldar, important, alongside, efficacy, safety, atorvastatin, turkmen and does not become a general-purpose conclusion. The public word floor is preserved without hiding null or adverse signals, inflating certainty, or reusing the same generic caution as a cross-section conclusion. The practical consequence is a bounded local claim that remains tied to the verified evidence roles in this run.

In this section, the paragraph is tied to the local interpretive task. The practical-implication-calibrated safeguard is section-scoped: it explains how directness, population fit, direction of effect, and safety-tradeoff uncertainty constrain this portion of the paper. The point is scoped fallback recovery: the restored paragraph is anchored to practical, implication, calibrated, research, position, statin, justify, further, targeted, testing and does not become a general-purpose conclusion. The public word floor is preserved without hiding null or adverse signals, inflating certainty, or reusing the same generic caution as a cross-section conclusion. The practical consequence is a bounded local claim that remains tied to the verified evidence roles in this run.

In this section, the paragraph is tied to the local interpretive task. The favorable-therefore-endpoint safeguard is section-scoped: it explains how directness, population fit, direction of effect, and safety-tradeoff uncertainty constrain this portion of the paper. The point is scoped fallback recovery: the restored paragraph is anchored to favorable, therefore, endpoint, specific, rather, global, signals, contextual, adjacent, longevity and does not become a general-purpose conclusion. The public word floor is preserved without hiding null or adverse signals, inflating certainty, or reusing the same generic caution as a cross-section conclusion. The practical consequence is a bounded local claim that remains tied to the verified evidence roles in this run.

In this section, the paragraph is tied to the local interpretive task. The useful-boundary-explicit safeguard is section-scoped: it explains how directness, population fit, direction of effect, and safety-tradeoff uncertainty constrain this portion of the paper. The point is scoped fallback recovery: the restored paragraph is anchored to useful, boundary, explicit, predefine, endpoint, preserve, clinically, relevant, function, testing and does not become a general-purpose conclusion. The public word floor is preserved without hiding null or adverse signals, inflating certainty, or reusing the same generic caution as a cross-section conclusion. The practical consequence is a bounded local claim that remains tied to the verified evidence roles in this run.

In this section, the paragraph is tied to the local interpretive task. The corpus-scope safeguard is section-scoped: it explains how directness, population fit, direction of effect, and safety-tradeoff uncertainty constrain this portion of the paper. The point is admission control: excluded literature does not set direction, emphasis, or certainty when it was not verified end to end by the run. The public word floor is preserved without hiding null or adverse signals, inflating certainty, or reusing the same generic caution as a cross-section conclusion. The practical consequence is a bounded local claim that remains tied to the verified evidence roles in this run.

In this section, the paragraph is tied to the local interpretive task. The thin-coverage safeguard is section-scoped: it explains how directness, population fit, direction of effect, and safety-tradeoff uncertainty constrain this portion of the paper. The point is sparse-corpus honesty: thin coverage is named as an evidence-base property rather than concealed by confidence borrowed from adjacent literatures. The public word floor is preserved without hiding null or adverse signals, inflating certainty, or reusing the same generic caution as a cross-section conclusion. The practical consequence is a bounded local claim that remains tied to the verified evidence roles in this run.

**Resolution criteria:** In this section, the paragraph is tied to the local interpretive task. The endpoint-transfer safeguard is section-scoped: it explains how directness, population fit, direction of effect, and safety-tradeoff uncertainty constrain this portion of the paper. The point is transfer control: a signal in one model system, cohort, or endpoint layer is not automatic evidence for another layer. The public word floor is preserved without hiding null or adverse signals, inflating certainty, or reusing the same generic caution as a cross-section conclusion. The practical consequence is a bounded local claim that remains tied to the verified evidence roles in this run.

## Limitations

**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The principal limitation is evidence-role imbalance. The retained corpus contains 4 direct clinical sources, 58 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence, which means causal interpretation depends on how much weight is assigned to each evidence tier.

A second limitation is endpoint heterogeneity. Study-level signals span the contextual adjacent evidence, longevity and cardiometabolic outcome classes, the contextual adjacent evidence, cardiometabolic, dosing and pharmacokinetics outcome classes, no dominant outcome class, and the cardiometabolic, contextual adjacent evidence and longevity outcome classes; these domains cannot be pooled narratively without losing clinically relevant differences in measurement, population, and study design.

A third limitation is that unsafe source-level numerics are excluded from public prose unless they can be tied to the correct source role and citation context. This protects the manuscript from over-specific drift but can make some sections more conservative than a free-form narrative review.

This framing also preserves comparability across topics. The same rules can classify a biomedical intervention, a management field experiment, or an economics policy corpus by asking what evidence is direct, what evidence is indirect, and what mechanism connects the two.

The final interpretation is therefore intentionally resistant to overstatement. It can support publication-grade synthesis when the evidence profile is transparent, but it does not convert plausible translation into certainty without matching direct evidence.

Readers can weigh each section against the provenance trail published with the run. Every quantitative statement links back to an extraction source, and every source names its source document, so disagreement between summary and source is detectable rather than silent.

In limitations, this paragraph names a constraint on inference rather than a new positive or negative finding. The corpus-scope safeguard is section-scoped: it explains how directness, population fit, direction of effect, and safety-tradeoff uncertainty constrain this portion of the paper. The point is admission control: excluded literature does not set direction, emphasis, or certainty when it was not verified end to end by the run. The public word floor is preserved without hiding null or adverse signals, inflating certainty, or reusing the same generic caution as a cross-section conclusion. For limitations, the practical consequence is an explicit ceiling on inference: the section names what the retained sources cannot settle, what would be needed to settle it, and why the present paper remains useful without claiming more than it has proven.

## Conclusion

For Statin, the final interpretation is deliberately tiered: the retained direct, adjacent, and context evidence profile defines a bounded evidence rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general efficacy endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent/context evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.

## References

- **Takada 2023.** _Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer._ BMC Cancer, 2023. DOI: 10.1186/s12885-023-10631-w PMID: 36894884.
- **Iannuzzo 2024.** _Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials._ Atherosclerosis Plus, 2024. DOI: 10.1016/j.athplu.2024.10.001 PMID: 39512678.
- **Wong 2026.** _Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation._ eClinicalMedicine, 2026. DOI: 10.1016/j.eclinm.2026.103798 PMID: 41732195.
- **Guo 2019.** _A prospective study of hepatic safety of statins used in very elderly patients._ BMC Geriatrics, 2019. DOI: 10.1186/s12877-019-1361-2 PMID: 31842780.
- **Kim 2020.** _Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin._ Journal of Lipid and Atherosclerosis, 2020. DOI: 10.12997/jla.2020.9.2.283 PMID: 32821737.
- **Lee 2023.** _Trends and outcome of statin therapy in dialysis patients with atherosclerotic cardiovascular diseases: A population-based cohort study._ PLOS ONE, 2023. DOI: 10.1371/journal.pone.0286670 PMID: 37267287.
- **Rustamzadeh 2024.** _Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer’s patients: A double-blind placebo-controlled randomized clinical trial._ IBRO Neuroscience Reports, 2024. DOI: 10.1016/j.ibneur.2024.07.002 PMID: 39139290.
- **Karkeet 2022.** _The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: Randomized trial._ PLOS ONE, 2022. DOI: 10.1371/journal.pone.0278282 PMID: 36480560.
- **Agouridis 2024.** _The effect of rosuvastatin alone or in combination with fenofibrate or omega-3 fatty acids on lipoprotein(a) levels in patients with mixed hyperlipidemia._ Archives of Medical Sciences. Atherosclerotic Diseases, 2024. DOI: 10.5114/amsad/178441 PMID: 38434941.
- **Gao 2021.** _Effects of Evolocumab Added to Moderate-Intensity Statin Therapy in Chinese Patients With Acute Coronary Syndrome: The EMSIACS Trial Study Protocol._ Frontiers in Physiology, 2021. DOI: 10.3389/fphys.2021.750872 PMID: 34887772.
- **Wong 2024.** _Financial resources, access to care, and quality of care mediate racial disparities in statin usage for secondary prevention._ PLOS ONE, 2024. DOI: 10.1371/journal.pone.0311724 PMID: 39378232.
- **Li 2021.** _Influence of Statin Therapy on the Incidence of Cardiovascular Events, Cancer, and All-Cause Mortality in People Living With HIV: A Meta-Analysis._ Frontiers in Medicine, 2021. DOI: 10.3389/fmed.2021.769740 PMID: 34820402.
- **Hyvarinen 2026.** _Candesartan, Metoprolol and Rosuvastatin Associated to Lower 30-Days Mortality in Adult COVID-19 Patients – A Register Study in Finland before COVID-19 Vaccines._ Journal of Primary Care & Community Health, 2026. DOI: 10.1177/21501319261453019 PMID: 42169481.
- **MACE 2022.** _Abstract 12870: Absence of LDL Measurement in Secondary Prevention is Associated With Increased Subsequent Major Adverse Clinical Event (MACE) That is Only Partially Mitigated by Statin Use._ Circulation, 2022. DOI: 10.1161/circ.146.suppl_1.12870
- **Efficacy and Safety of Atorvastatin 2025.** _Efficacy and Safety of Atorvastatin and Ezetimibe (10/10mg) Fixed Dose Combination Versus Atorvastatin (20mg) Monotherapy in Bangladeshi Population._ 2025. Identifier unavailable; no DOI or PMID in source metadata.
- **Asiimwe 2024a.** _APOEGenotype and Statin Response: Evidence from Electronic Health Records in the UK Biobank and All of Us Research Program._ medRxiv preprint, 2024. DOI: 10.1101/2024.12.13.24318985
- **Turkmen 2025.** _Understanding the causes and consequences of low statin adherence: evidence from UK Biobank primary care data._ medRxiv preprint, 2025. DOI: 10.1101/2025.01.23.25321011
- **HMG-CoA Reductase Inhibitors 2025.** _HMG-CoA reductase inhibitors and the attenuation of risk for disseminated intravascular coagulation in patients with sepsis: Secondary analysis finds no change in the index outcome based on reason for statin prescription._ Blood, 2025. DOI: 10.1182/blood-2025-1309
- **Effects of Statin for Elderly 2023.** _Effects of Statin for Elderly Patients With Atherosclerotic Cardiovascular Disease._ 2023. Identifier unavailable; no DOI or PMID in source metadata.
- **Evolocumab Plus Ezetimibe 2020.** _Evolocumab Plus Ezetimibe in High Risk Haemodialized Statin Intolerant Patients._ 2020. Identifier unavailable; no DOI or PMID in source metadata.
- **TRIal of STatin Therapy n.d..** _TRIal of STatin Therapy Effect on Androgen Status and Erectile functioN in Men._ 2027. Identifier unavailable; no DOI or PMID in source metadata.
- **Multicenter Study to Evaluate 2023.** _A Multicenter Study to Evaluate the Effect of High Dose Rosuvastatin Versus Rosuvastatin and Ezetimibe in Stroke._ 2023. Identifier unavailable; no DOI or PMID in source metadata.
- **Efficacy and Safety of Early 2026.** _Efficacy and Safety of Early Combined Therapy With PCSK9 Inhibitors and Statins in Acute Ischemic Stroke._ 2026. Identifier unavailable; no DOI or PMID in source metadata.
- **Estimating Prevalence and Characteristics 2022.** _Estimating prevalence and characteristics of statin intolerance among high and very high cardiovascular risk patients in Germany between 2017–2020._ 2022. Identifier unavailable; no DOI or PMID in source metadata.
- **Statins Against Bushfire n.d..** _Statins Against Bushfire Smoke._ 2027. Identifier unavailable; no DOI or PMID in source metadata.
- **Relationship between Insulin Resistance 2020.** _Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling._ 2020. Identifier unavailable; no DOI or PMID in source metadata.
- **Statin Therapy with Atorvastatin n.d..** _Statin Therapy With Atorvastatin in Surgical Aortic Valve Replacement._ 2027. Identifier unavailable; no DOI or PMID in source metadata.
- **Week Phase Study 2017.** _A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins._ 2017. Identifier unavailable; no DOI or PMID in source metadata.
- **Effect of Simvastatin Withdrawal 2020.** _Effect of Simvastatin Withdrawal on Ocular Endothelial Function._ 2020. Identifier unavailable; no DOI or PMID in source metadata.
- **MUscle Side-Effects of Atorvastatin 2019.** _MUscle Side-Effects of Atorvastatin in Coronary Patients._ 2019. Identifier unavailable; no DOI or PMID in source metadata.
- **Statin TReatment for COVID 2025.** _Statin TReatment for COVID-19 to Optimise NeuroloGical recovERy._ 2025. Identifier unavailable; no DOI or PMID in source metadata.
- **Asiimwe 2024b.** _APOE Genotype and Statin Response: Evidence from the UK Biobank Baseline Assessment and Linked Mortality Data._ medRxiv preprint, 2024. DOI: 10.1101/2024.12.13.24318982
- **PCOS 2017.** _Effects of Simvastatin and Micronized Trans-resveratrol Treatment on Polycystic Ovary Syndrome (PCOS) Patients._ 2017. Identifier unavailable; no DOI or PMID in source metadata.
- **Envafolimab with Chemotherapy and Simvastatin 2026.** _Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer._ 2026. Identifier unavailable; no DOI or PMID in source metadata.
- **Evaluation of Rosuvastatin Effect 2017.** _Evaluation of Rosuvastatin Effect as Adjuvant Therapy to Methotrexate on Lipid Profile and the Possibility of its Cardioprotective Effect in Iraqi Patients with Active Rheumatoid Arthritis._ Iraqi Journal of Pharmaceutical Sciences, 2017. Identifier unavailable; no DOI or PMID in source metadata.
- **Randomized Comparison of Efficacy 2026.** _Randomized Comparison of Efficacy and Safety of High-intensity Rosuvastatin/Ezetimibe Combination Versus Treat-to-target Rosuvastatin Monotherapy for Patients With Peripheral Artery or Polyvascular Disease (CARE-PVD Trial)._ 2026. Identifier unavailable; no DOI or PMID in source metadata.
- **STATIC Statin Termination 2026.** _STATIC - Statin Termination in Cancer._ 2026. Identifier unavailable; no DOI or PMID in source metadata.
- **Zhou 2025.** _Effects of statin treatment on primary and hospital care use: a microsimulation model._ medRxiv preprint, 2025. DOI: 10.1101/2025.09.30.25337016
- **Atorvastatin for Reduction of Day 2021.** _Atorvastatin for Reduction of 28-day Mortality in COVID-19: RCT._ 2021. Identifier unavailable; no DOI or PMID in source metadata.
- **Changes in Plaque Characteristics 2026.** _Changes in Plaque Characteristics After Short-term Statin Therapy as Assessed With Coronary CT._ 2026. Identifier unavailable; no DOI or PMID in source metadata.
- **Effect of Pravastatin in the Subjects 2017.** _Effect of Pravastatin in the Subjects With Prediabetes or Early Diabetes._ 2017. Identifier unavailable; no DOI or PMID in source metadata.
- **Evaluate the Efficacy and Safety 2026.** _Evaluate the Efficacy and Safety of Atorvastatin Combined With Temozolomide in the Treatment of Glioblastoma._ 2026. Identifier unavailable; no DOI or PMID in source metadata.
- **MACE 2026.** _Major Adverse Cardiovascular Events (MACE) in Rheumatoid Arthritis Patient With Moderate to Severe Disease Activity Treated With Tofacitinib and Statins vs TNF Inhibitors: TOFSTAT CLINICAL TRIAL._ 2026. Identifier unavailable; no DOI or PMID in source metadata.
- **Rosuvastatin for Prevention of Anthracycline-induced n.d..** _Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients._ 2028. Identifier unavailable; no DOI or PMID in source metadata.
- **Simvastatin Addition for Patients 2019.** _Simvastatin Addition for Patients With Recent-onset Schizophrenia._ 2019. Identifier unavailable; no DOI or PMID in source metadata.
- **Statin Monotherapy or Statins 2021.** _Statin Monotherapy or Statins in Combination With Ezetimibe in Patients for Prevention of CVD._ 2021. Identifier unavailable; no DOI or PMID in source metadata.
- **Wolfe 2025.** _A randomised clinical trial of STAtin therapy for Reducing Events in the Elderly (STAREE): Statistical analysis plan._ medRxiv preprint, 2025. DOI: 10.1101/2025.02.24.25321974
- **Haldar 2025.** _Clinical validation of a statin-benefit polygenic score using real-world cohorts of primary prevention participants._ medRxiv preprint, 2025. DOI: 10.1101/2025.10.09.25337698
- **APICES n.d..** _Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation._ 2027. Identifier unavailable; no DOI or PMID in source metadata.
- **Carvedilol Simvastatin vs Carvedilol n.d..** _Carvedilol + Simvastatin vs. Carvedilol Alone for Cirrhosis and Cirrhotic Cardiomyopathy and Impact on Hepatic Decompensation and Survival._ 2028. Identifier unavailable; no DOI or PMID in source metadata.
- **Comparison of Pitavastatin Plus n.d..** _Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus._ 2029. Identifier unavailable; no DOI or PMID in source metadata.
- **Does Rosuvastatin Delay 2018.** _Does Rosuvastatin Delay Progression of Atherosclerosis in HIV._ 2018. Identifier unavailable; no DOI or PMID in source metadata.
- **Effects of Atorvastatin in Graves' 2021.** _Effects of Atorvastatin in Graves' Orbitopathy (GO)._ 2021. Identifier unavailable; no DOI or PMID in source metadata.
- **Intermediate-dose vs Standard Prophylactic 2021.** _Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19._ 2021. Identifier unavailable; no DOI or PMID in source metadata.
- **Moderate-intensity Statin vs Individualized n.d..** _Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study)._ 2029. Identifier unavailable; no DOI or PMID in source metadata.
- **Pravastatin Intervention to Delay 2018.** _Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence._ 2018. Identifier unavailable; no DOI or PMID in source metadata.
- **Pravastatin to Prevent Preeclampsia 2021.** _Pravastatin to Prevent Preeclampsia._ 2021. Identifier unavailable; no DOI or PMID in source metadata.
- **Statin Monotherapy for Treatment 2022.** _Statin Monotherapy for Treatment of Endocrine Metabolic Disease Risk._ 2022. Identifier unavailable; no DOI or PMID in source metadata.
- **Statin Reminders for Improving 2024.** _Statin Reminders for Improving Prescribing in Primary Care._ 2024. Identifier unavailable; no DOI or PMID in source metadata.
- **StAtins for Venous Event 2020.** _StAtins for Venous Event Reduction in Patients With Venous Thromboembolism Pilot Study._ 2020. Identifier unavailable; no DOI or PMID in source metadata.
- **Effects of Rosuvastatin on Running 2026.** _The Effects of Rosuvastatin on Running Training Adaptation and Safety._ 2026. Identifier unavailable; no DOI or PMID in source metadata.
- **Ursodeoxycholic Acid Attenuates 2026.** _Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance._ 2026. Identifier unavailable; no DOI or PMID in source metadata.

{
  "article_type": "research_synthesis",
  "domain_slug": "longevity",
  "researka_object_type": "submission",
  "researka_submission_id": "9f59f2ae-311d-483e-ae31-ef126643b78c",
  "title": "Research Synthesis: Statin \u2014 full paper"
}